Results 161 to 170 of about 1,444,780 (246)

Signal detection and characterisation of a novel drug–drug interaction between methadone and a synthetic cannabinoid receptor agonist

British Journal of Pharmacology, EarlyView.
Background and Purpose Little is known about how synthetic cannabinoid receptor agonist (SCRA) co‐use with other psychoactive substances may exacerbate risk of death. This study aimed to characterise the polypharmacy of deaths where SCRAs were detected at post‐mortem, investigate the cardiotoxicity of SCRAs and probe their inhibition of human ether‐a ...
Kirsten L. Rock, Louise M. Hesketh, Hongwei Cheng, Shuoqi Chen, Simon Hudson, Graeme Henderson, Jules C. Hancox, Michael J. Shattock, Michael J. Curtis, Caroline S. Copeland   +9 more
wiley   +1 more source

Plasma EC90 multiples are drug, target site and species specific—A physiologically based pharmacokinetic modelling example of nirmatrelvir central nervous system distribution

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Achieving minimum unbound drug concentration in plasma above in vitro EC90 is a common antiviral pharmacokinetic/pharmacodynamic (PK/PD) target. However, it often overlooks restricted distribution into target sites like the central nervous system (CNS), where a trough concentration above 1 × EC90 is needed.
Daan W. van Valkengoed, Xuanlin Liu, Sean N. Avedissian, Courtney V. Fletcher, Ashley N. Brown, Elizabeth C. M. de Lange, Anne‐Grete Märtson   +6 more
wiley   +1 more source

Quizartinib Resistance Mutations and Treatment Outcomes in Relapsed or Refractory FLT3‐ITD–Positive AML

Cancer Science, EarlyView.
ABSTRACT Quizartinib is a FMS‐like tyrosine kinase 3 (FLT3) inhibitor indicated for FLT3 internal tandem duplication (FLT3‐ITD)–positive acute myeloid leukemia (AML). We aimed to evaluate quizartinib resistance mechanisms, in addition to efficacy and safety outcomes, in patients with relapsed or refractory FLT3‐ITD–positive AML.
Yuichiro Semba, Toshihiro Miyamoto, Senji Kasahara, Yoshikane Kikushige, Takahiro Maeda, Goichi Yoshimoto, Shuichi Ota, Akio Saito, Yuho Najima, Hiroki Hosoi, Daigo Niiya, Koji Kato, Koji Nagafuji, Takashi Akasaka, Tomohiko Kamimura, Atsushi Takita, Maiko Narahara, Tadashi Toki, Koichi Iwanaga, Koji Yonemoto, Mine Harada, Koichi Akashi   +21 more
wiley   +1 more source

QT Interval Prolongation and Beyond [PDF]

Annals of Noninvasive Electrocardiology, 2006
openaire   +1 more source

Incentives and motivational crowding to address chronic wasting disease: An experiment with Alberta hunters

Canadian Journal of Agricultural Economics/Revue canadienne d'agroeconomie, EarlyView.
Abstract Behavioral interventions, for example, through the use of incentives and information, are widely used by policymakers to induce welfare‐improving behavior. When these interventions are used in specific contexts such as environmental conservation, individual knowledge, experience, and attitudes can lead to motivational crowding and may limit ...
Lusi Xie, Maik Kecinski, Wiktor Adamowicz   +2 more
wiley   +1 more source

Pharmacological and non‐pharmacological interventions for managing sleep disorders in children with cerebral palsy: A systematic review

Developmental Medicine &Child Neurology, EarlyView.
xxxxxx Aim To systematically review the effectiveness, safety, and economic evidence of pharmacological and non‐pharmacological interventions for sleep disorders in children with cerebral palsy (CP). Method Databases including MEDLINE, Embase, CENTRAL (the Cochrane Library), International Clinical Trials Registry Platform of the World Health ...
Nishant Jaiswal, Lizzie Fisher, Giorgio Ciminata, Ryan Mulholland, Anna Noel‐Storr, Lesley Nutton, Valerie Orr, Paul Eunson, Nicola J. Cooper, Alex Sutton, Olivia Wu, Terry Quinn   +11 more
wiley   +1 more source

Obesity and QT interval prolongation

Journal of the Japanese Society of Intensive Care Medicine, 2007
Iwasaki, Yu-ki, Tanaka, Keiji
openaire   +2 more sources

Hypoglycaemia care: Time to modernise our treatment standards

Diabetic Medicine, EarlyView.
This editorial argues that hypoglycaemia self care should move beyond ‘any sugar will do’ and define what good recovery after treatment should involve. It proposes recovery‐focused standards using CGM metrics, such as time‐in‐range and repeat lows after treatment, alongside participant‐reported recovery, so existing and emerging approaches, including ...
David Russell‐Jones, Julia K. Mader
wiley   +1 more source

Intravenous Oxytocin Does Not Affect Glucose‐Regulating Hormones or Markers of Bone Turnover During Graded Glucose Infusion in Healthy Men

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim Oxytocin has been proposed to exert glucose‐stabilising effects via modulation of pancreatic hormone secretion and to play a role in bone homeostasis. However, human data under controlled conditions are limited. We investigated the effects of intravenously infused oxytocin during a graded glucose infusion on glucose‐regulating hormones and
Vivian Kliim‐Hansen, Ida M. Gether, Aliya M. Thomas, Anne‐Marie Ellegaard, Miriam G. Pedersen, Jens J. Holst, Bolette Hartmann, Filip K. Knop, Lærke S. Gasbjerg, Asger B. Lund   +9 more
wiley   +1 more source

Safety, Tolerability, Pharmacokinetics and Exploratory Pharmacodynamics of Melanin‐Concentrating Hormone Receptor‐1 Antagonist RGH‐706 in Healthy and Overweight or Obese Men

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim This Phase 1 program evaluated the safety, tolerability, pharmacokinetics and exploratory pharmacodynamics of the novel melanin‐concentrating hormone receptor‐1 antagonist RGH‐706. Methods Study A was a first‐in‐man, randomized trial comprising a double‐blind, placebo‐controlled single‐ascending‐dose part (0.1–162.5 mg) and a two‐way ...
Thomas Brevig, Borbála Szepes, Zsófia Borbála Dombi, Gabriella Magyar, Zoltán Juhász, Margit Kapás, Éva Cseh, Zsuzsa Hegedűs, Tibor Farkas, Zsuzsanna Kiss, Balázs Szatmári   +10 more
wiley   +1 more source